About 1,308 results

ALLMedicine™ Leukoencephalopathy Center

Research & Reviews  429 results

Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematos...
International Journal of Rheumatic Diseases; Gomathy S, Panigrahi B et. al.

May 11th, 2022 - Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating central nervous system illness encountered in the setting of immunosuppressive conditions like human immunodeficiency virus / acquired immunodeficiency syndrome, autoimmune d...

Notch Signaling in Vascular Endothelial and Mural Cell Communications.
Cold Spring Harbor Perspectives in Medicine; O'Hare M, Arboleda-Velasquez JF

May 10th, 2022 - The Notch signaling pathway is a highly versatile and evolutionarily conserved mechanism with an important role in cell fate determination. Notch signaling plays a vital role in vascular development, regulating several fundamental processes such a...

R558C NOTCH3 Mutation in a CADASIL Patient with Intracerebral Hemorrhage: A Case Report...
Journal of Stroke and Cerebrovascular Diseases : the Offi... Hu L, Liu G et. al.

May 7th, 2022 - Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a monogenic cerebral small-vessel disease, which is characterized by migraine, recurrent ischemic strokes, psychiatric disorder, progressive co...

Pathogenicity analysis and a novel case report of intronic mutations in CSF1R gene.
Neurocase Shixing X, Wei W et. al.

May 4th, 2022 - Colony-stimulating factor 1 receptor-associated leukoencephalopathy (CSF1R-related leukoencephalopathy) is a genetic disorder mutated in a single allele. It is characterized by an adult-onset along with predominantly cognitive impairment, accompan...

Single-center experience on progressive multifocal leukoencephalopathy (PML) cases, neu...
Journal of Medical Virology; Yu H, Wu H et. al.

Apr 23rd, 2022 - Progressive multifocal leukoencephalopathy (PML) is an increasingly common and rapidly fatal demyelinating infection of central nervous system caused by the highly prevalent John Cunningham (JC) virus in immunocompromised individuals belonging to ...

see more →

News  94 results

Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy

May 5th, 2022 - Most patients with relapsing-remitting multiple sclerosis (RRMS) who are stable on natalizumab (Tysabri, Biogen) administered once every 4 weeks (Q4W) may be able to safely switch to a once every 6 weeks (Q6W) dosing interval with no clinically me...

First Case of PML Associated With Ocrelizumab Monotherapy

Mar 19th, 2021 - A 78-year-old man with progressive multiple sclerosis (MS) developed progressive multifocal leukoencephalopathy (PML) after treatment with ocrelizumab (Ocrevus) monotherapy. It is believed to be the first such case. "Notably, the patient had never...

Fast Five Quiz: Relapsing-Remitting Multiple Sclerosis Management

Sep 4th, 2020 - Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection of the brain that can lead to severe disability or death. Natalizumab has been associated with PML. Risk factors for PML are previous immunosuppression, duration of exp...

Report Details First Case of PML With Ocrelizumab Alone

Apr 30th, 2020 - The first case of progressive multifocal leukoencephalopathy (PML) directly associated with ocrelizumab occurred in a patient with primary progressive multiple sclerosis (MS) who received 2 years of ocrelizumab monotherapy and had not received pri...

Immunotherapy induces improvements in PML
Andrew D. Bowser

May 6th, 2019 - Philadelphia – Adoptive transfer of donor-derived T cells represents a potentially life-saving treatment of severely immunocompromised patients with progressive multifocal leukoencephalopathy (PML). Courtesy NIH/NINDS Dr.

see more →